Global Nonalcoholic Steatohepatitis Treatment Market

Nonalcoholic Steatohepatitis Treatment Comprehensive Study by Type (Lifestyle Modifications, Dietary Changes, Exercise), Application (Health and Nutrition Tracking Apps, Medication Management Tools), Distribution (Hospital Pharmacy, Online Provider, Retail Pharmacy), Medication (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2030

Nonalcoholic Steatohepatitis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Nonalcoholic Steatohepatitis Treatment Market Scope
Non-alcoholic fatty liver disease, defined as the development of macrovascular steatosis in the presence of less than 20 grammes of alcohol intake per day, is the most prevalent liver disease in the Western world. It is most often related with insulin resistance/type 2 diabetes mellitus and obesity. It manifests as steatosis, steatohepatitis, cirrhosis, and, in rare cases, hepatocellular cancer. Hepatic steatosis is caused by an imbalance between fat absorption, oxidation, and export. Insulin resistance, which predisposes to lipolysis of peripheral fat and mobilisation and absorption of fatty acids by the liver, is the most constant underlying pathogenic cause. The growing clinical and economic burden of NAFLD has emphasised the need for a more simplified approach to disease prevention, diagnosis, and treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAllergan plc. (United States), Cadila Healthcare Limited (India), Conatus Pharmaceuticals Inc. (United States), Galmed Pharmaceuticals Ltd (Israel), Gemphire Therapeutics Inc. (United States), Genfit SA (France) and Gilead Sciences, Inc. (United States)
CAGR%


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Nonalcoholic Steatohepatitis Treatment market throughout the predicted period.

Allergan plc. (United States), Cadila Healthcare Limited (India), Conatus Pharmaceuticals Inc. (United States), Galmed Pharmaceuticals Ltd (Israel), Gemphire Therapeutics Inc. (United States), Genfit SA (France) and Gilead Sciences, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Intercept Pharmaceuticals, Inc. (United States), Novartis International AG (Switzerland) and Shire Plc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Nonalcoholic Steatohepatitis Treatment market by Type , by Application (Health and Nutrition Tracking Apps and Medication Management Tools) and Region with country level break-up.

On the basis of geography, the market of Nonalcoholic Steatohepatitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In May 2017 Novartis announced that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercialization of emricasan, under the option, collaboration and license agreement signed with Conatus on December 19, 2016. The exercise of the option with Conatus, a biotechnology company focused on the development of novel medicines to treat liver disease, and grant of exclusive license to Novartis will be effective upon receipt of all required anti-trust approvals and payment of USD 7 million option exercise fee to Conatus.
In March 2020 - Zydus Cadila Launched Drug for NASH. The Launched Was Followed by Drug Controller General of India (DCGI) Approval to Zydus’s “Saroglitazar” for Treatment of Non-Cirrhotic, Non-Alcoholic Steatohepatitis (NASH) In India, Making It the First-Ever Drug for Treatment of The Disease.


Influencing Trend:
Rising Geriatric Population

Market Growth Drivers:
Prevalence of Nonalcoholic Steatohepatitis Cases and High Investment in Pharmaceutical R&D

Challenges:
Fierce Competitive Pressure

Restraints:
Lack of Skilled Professionals and Side Effects and Adverse Reactions

Opportunities:
Growing Healthcare Infrastructure Across Emerging Regions

Key Target Audience
Nonalcoholic Steatohepatitis Treatment Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Lifestyle Modifications
  • Dietary Changes
  • Exercise
By Application
  • Health and Nutrition Tracking Apps
  • Medication Management Tools
By Distribution
  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy

By Medication
  • Vitamin E & Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib & Cenicriviroc

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Nonalcoholic Steatohepatitis Cases
      • 3.2.2. High Investment in Pharmaceutical R&D
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nonalcoholic Steatohepatitis Treatment, by Type, Application, Distribution, Medication, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nonalcoholic Steatohepatitis Treatment (Value)
      • 5.2.1. Global Nonalcoholic Steatohepatitis Treatment by: Type (Value)
        • 5.2.1.1. Lifestyle Modifications
        • 5.2.1.2. Dietary Changes
        • 5.2.1.3. Exercise
      • 5.2.2. Global Nonalcoholic Steatohepatitis Treatment by: Application (Value)
        • 5.2.2.1. Health and Nutrition Tracking Apps
        • 5.2.2.2. Medication Management Tools
      • 5.2.3. Global Nonalcoholic Steatohepatitis Treatment by: Distribution (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Online Provider
        • 5.2.3.3. Retail Pharmacy
      • 5.2.4. Global Nonalcoholic Steatohepatitis Treatment by: Medication (Value)
        • 5.2.4.1. Vitamin E & Pioglitazone
        • 5.2.4.2. Ocaliva
        • 5.2.4.3. Elafibranor
        • 5.2.4.4. Selonsertib & Cenicriviroc
      • 5.2.5. Global Nonalcoholic Steatohepatitis Treatment by: End User (Value)
        • 5.2.5.1. Pediatric
        • 5.2.5.2. Adult
        • 5.2.5.3. Geriatric
      • 5.2.6. Global Nonalcoholic Steatohepatitis Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Nonalcoholic Steatohepatitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cadila Healthcare Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Conatus Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Galmed Pharmaceuticals Ltd (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gemphire Therapeutics Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genfit SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gilead Sciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Nonalcoholic Steatohepatitis Treatment Sale, by Type, Application, Distribution, Medication, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nonalcoholic Steatohepatitis Treatment (Value)
      • 7.2.1. Global Nonalcoholic Steatohepatitis Treatment by: Type (Value)
        • 7.2.1.1. Lifestyle Modifications
        • 7.2.1.2. Dietary Changes
        • 7.2.1.3. Exercise
      • 7.2.2. Global Nonalcoholic Steatohepatitis Treatment by: Application (Value)
        • 7.2.2.1. Health and Nutrition Tracking Apps
        • 7.2.2.2. Medication Management Tools
      • 7.2.3. Global Nonalcoholic Steatohepatitis Treatment by: Distribution (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Online Provider
        • 7.2.3.3. Retail Pharmacy
      • 7.2.4. Global Nonalcoholic Steatohepatitis Treatment by: Medication (Value)
        • 7.2.4.1. Vitamin E & Pioglitazone
        • 7.2.4.2. Ocaliva
        • 7.2.4.3. Elafibranor
        • 7.2.4.4. Selonsertib & Cenicriviroc
      • 7.2.5. Global Nonalcoholic Steatohepatitis Treatment by: End User (Value)
        • 7.2.5.1. Pediatric
        • 7.2.5.2. Adult
        • 7.2.5.3. Geriatric
      • 7.2.6. Global Nonalcoholic Steatohepatitis Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nonalcoholic Steatohepatitis Treatment: by Type(USD Million)
  • Table 2. Nonalcoholic Steatohepatitis Treatment Lifestyle Modifications , by Region USD Million (2018-2023)
  • Table 3. Nonalcoholic Steatohepatitis Treatment Dietary Changes , by Region USD Million (2018-2023)
  • Table 4. Nonalcoholic Steatohepatitis Treatment Exercise , by Region USD Million (2018-2023)
  • Table 5. Nonalcoholic Steatohepatitis Treatment: by Application(USD Million)
  • Table 6. Nonalcoholic Steatohepatitis Treatment Health and Nutrition Tracking Apps , by Region USD Million (2018-2023)
  • Table 7. Nonalcoholic Steatohepatitis Treatment Medication Management Tools , by Region USD Million (2018-2023)
  • Table 8. Nonalcoholic Steatohepatitis Treatment: by Distribution(USD Million)
  • Table 9. Nonalcoholic Steatohepatitis Treatment Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 10. Nonalcoholic Steatohepatitis Treatment Online Provider , by Region USD Million (2018-2023)
  • Table 11. Nonalcoholic Steatohepatitis Treatment Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 12. Nonalcoholic Steatohepatitis Treatment: by Medication(USD Million)
  • Table 13. Nonalcoholic Steatohepatitis Treatment Vitamin E & Pioglitazone , by Region USD Million (2018-2023)
  • Table 14. Nonalcoholic Steatohepatitis Treatment Ocaliva , by Region USD Million (2018-2023)
  • Table 15. Nonalcoholic Steatohepatitis Treatment Elafibranor , by Region USD Million (2018-2023)
  • Table 16. Nonalcoholic Steatohepatitis Treatment Selonsertib & Cenicriviroc , by Region USD Million (2018-2023)
  • Table 17. Nonalcoholic Steatohepatitis Treatment: by End User(USD Million)
  • Table 18. Nonalcoholic Steatohepatitis Treatment Pediatric , by Region USD Million (2018-2023)
  • Table 19. Nonalcoholic Steatohepatitis Treatment Adult , by Region USD Million (2018-2023)
  • Table 20. Nonalcoholic Steatohepatitis Treatment Geriatric , by Region USD Million (2018-2023)
  • Table 21. South America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2018-2023)
  • Table 22. South America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 23. South America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 24. South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 25. South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 26. South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 27. Brazil Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 28. Brazil Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 29. Brazil Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 30. Brazil Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 31. Brazil Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 32. Argentina Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 33. Argentina Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 34. Argentina Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 35. Argentina Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 36. Argentina Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 37. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 38. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 39. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 40. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 41. Rest of South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 42. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2018-2023)
  • Table 43. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 44. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 46. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 47. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 48. China Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 49. China Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 50. China Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 51. China Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 52. China Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 53. Japan Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 54. Japan Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 55. Japan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 56. Japan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 57. Japan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 58. India Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 59. India Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 60. India Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 61. India Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 62. India Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 63. South Korea Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 64. South Korea Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 65. South Korea Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 66. South Korea Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 67. South Korea Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 68. Taiwan Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 69. Taiwan Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 70. Taiwan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 71. Taiwan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 72. Taiwan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 73. Australia Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 74. Australia Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 75. Australia Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 76. Australia Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 77. Australia Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 83. Europe Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2018-2023)
  • Table 84. Europe Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 85. Europe Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 86. Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 87. Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 88. Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 89. Germany Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 90. Germany Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 91. Germany Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 92. Germany Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 93. Germany Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 94. France Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 95. France Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 96. France Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 97. France Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 98. France Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 99. Italy Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 100. Italy Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 101. Italy Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 102. Italy Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 103. Italy Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 104. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 105. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 106. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 107. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 108. United Kingdom Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 109. Netherlands Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 110. Netherlands Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 111. Netherlands Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 112. Netherlands Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 113. Netherlands Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 114. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 115. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 116. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 117. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 118. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 119. MEA Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2018-2023)
  • Table 120. MEA Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 121. MEA Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 122. MEA Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 123. MEA Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 124. MEA Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 125. Middle East Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 126. Middle East Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 127. Middle East Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 128. Middle East Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 129. Middle East Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 130. Africa Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 131. Africa Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 132. Africa Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 133. Africa Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 134. Africa Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 135. North America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2018-2023)
  • Table 136. North America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 137. North America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 138. North America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 139. North America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 140. North America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 141. United States Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 142. United States Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 143. United States Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 144. United States Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 145. United States Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 146. Canada Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 147. Canada Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 148. Canada Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 149. Canada Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 150. Canada Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 151. Mexico Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2018-2023)
  • Table 152. Mexico Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2018-2023)
  • Table 153. Mexico Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2018-2023)
  • Table 154. Mexico Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2018-2023)
  • Table 155. Mexico Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2018-2023)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Nonalcoholic Steatohepatitis Treatment: by Type(USD Million)
  • Table 164. Nonalcoholic Steatohepatitis Treatment Lifestyle Modifications , by Region USD Million (2025-2030)
  • Table 165. Nonalcoholic Steatohepatitis Treatment Dietary Changes , by Region USD Million (2025-2030)
  • Table 166. Nonalcoholic Steatohepatitis Treatment Exercise , by Region USD Million (2025-2030)
  • Table 167. Nonalcoholic Steatohepatitis Treatment: by Application(USD Million)
  • Table 168. Nonalcoholic Steatohepatitis Treatment Health and Nutrition Tracking Apps , by Region USD Million (2025-2030)
  • Table 169. Nonalcoholic Steatohepatitis Treatment Medication Management Tools , by Region USD Million (2025-2030)
  • Table 170. Nonalcoholic Steatohepatitis Treatment: by Distribution(USD Million)
  • Table 171. Nonalcoholic Steatohepatitis Treatment Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 172. Nonalcoholic Steatohepatitis Treatment Online Provider , by Region USD Million (2025-2030)
  • Table 173. Nonalcoholic Steatohepatitis Treatment Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 174. Nonalcoholic Steatohepatitis Treatment: by Medication(USD Million)
  • Table 175. Nonalcoholic Steatohepatitis Treatment Vitamin E & Pioglitazone , by Region USD Million (2025-2030)
  • Table 176. Nonalcoholic Steatohepatitis Treatment Ocaliva , by Region USD Million (2025-2030)
  • Table 177. Nonalcoholic Steatohepatitis Treatment Elafibranor , by Region USD Million (2025-2030)
  • Table 178. Nonalcoholic Steatohepatitis Treatment Selonsertib & Cenicriviroc , by Region USD Million (2025-2030)
  • Table 179. Nonalcoholic Steatohepatitis Treatment: by End User(USD Million)
  • Table 180. Nonalcoholic Steatohepatitis Treatment Pediatric , by Region USD Million (2025-2030)
  • Table 181. Nonalcoholic Steatohepatitis Treatment Adult , by Region USD Million (2025-2030)
  • Table 182. Nonalcoholic Steatohepatitis Treatment Geriatric , by Region USD Million (2025-2030)
  • Table 183. South America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2025-2030)
  • Table 184. South America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 185. South America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 186. South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 187. South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 188. South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 189. Brazil Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 190. Brazil Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 191. Brazil Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 192. Brazil Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 193. Brazil Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 194. Argentina Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 195. Argentina Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 196. Argentina Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 197. Argentina Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 198. Argentina Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 199. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 200. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 201. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 202. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 203. Rest of South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 204. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2025-2030)
  • Table 205. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 206. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 207. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 208. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 209. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 210. China Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 211. China Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 212. China Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 213. China Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 214. China Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 215. Japan Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 216. Japan Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 217. Japan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 218. Japan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 219. Japan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 220. India Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 221. India Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 222. India Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 223. India Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 224. India Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 225. South Korea Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 226. South Korea Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 227. South Korea Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 228. South Korea Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 229. South Korea Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 230. Taiwan Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 231. Taiwan Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 232. Taiwan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 233. Taiwan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 234. Taiwan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 235. Australia Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 236. Australia Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 237. Australia Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 238. Australia Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 239. Australia Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 240. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 241. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 242. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 243. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 244. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 245. Europe Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2025-2030)
  • Table 246. Europe Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 247. Europe Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 248. Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 249. Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 250. Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 251. Germany Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 252. Germany Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 253. Germany Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 254. Germany Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 255. Germany Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 256. France Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 257. France Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 258. France Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 259. France Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 260. France Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 261. Italy Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 262. Italy Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 263. Italy Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 264. Italy Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 265. Italy Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 266. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 267. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 268. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 269. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 270. United Kingdom Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 271. Netherlands Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 272. Netherlands Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 273. Netherlands Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 274. Netherlands Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 275. Netherlands Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 276. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 277. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 278. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 279. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 280. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 281. MEA Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2025-2030)
  • Table 282. MEA Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 283. MEA Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 284. MEA Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 285. MEA Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 286. MEA Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 287. Middle East Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 288. Middle East Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 289. Middle East Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 290. Middle East Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 291. Middle East Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 292. Africa Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 293. Africa Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 294. Africa Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 295. Africa Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 296. Africa Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 297. North America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2025-2030)
  • Table 298. North America Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 299. North America Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 300. North America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 301. North America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 302. North America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 303. United States Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 304. United States Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 305. United States Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 306. United States Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 307. United States Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 308. Canada Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 309. Canada Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 310. Canada Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 311. Canada Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 312. Canada Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 313. Mexico Nonalcoholic Steatohepatitis Treatment, by Type USD Million (2025-2030)
  • Table 314. Mexico Nonalcoholic Steatohepatitis Treatment, by Application USD Million (2025-2030)
  • Table 315. Mexico Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2025-2030)
  • Table 316. Mexico Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2025-2030)
  • Table 317. Mexico Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2025-2030)
  • Table 318. Research Programs/Design for This Report
  • Table 319. Key Data Information from Secondary Sources
  • Table 320. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nonalcoholic Steatohepatitis Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Nonalcoholic Steatohepatitis Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Nonalcoholic Steatohepatitis Treatment: by Distribution USD Million (2018-2023)
  • Figure 7. Global Nonalcoholic Steatohepatitis Treatment: by Medication USD Million (2018-2023)
  • Figure 8. Global Nonalcoholic Steatohepatitis Treatment: by End User USD Million (2018-2023)
  • Figure 9. South America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 10. Asia Pacific Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 11. Europe Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 12. MEA Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 13. North America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 14. Global Nonalcoholic Steatohepatitis Treatment share by Players 2023 (%)
  • Figure 15. Global Nonalcoholic Steatohepatitis Treatment share by Players (Top 3) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Allergan plc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Allergan plc. (United States) Revenue: by Geography 2023
  • Figure 19. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 20. Cadila Healthcare Limited (India) Revenue: by Geography 2023
  • Figure 21. Conatus Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Conatus Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Galmed Pharmaceuticals Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Galmed Pharmaceuticals Ltd (Israel) Revenue: by Geography 2023
  • Figure 25. Gemphire Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Gemphire Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Genfit SA (France) Revenue, Net Income and Gross profit
  • Figure 28. Genfit SA (France) Revenue: by Geography 2023
  • Figure 29. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Global Nonalcoholic Steatohepatitis Treatment: by Type USD Million (2025-2030)
  • Figure 32. Global Nonalcoholic Steatohepatitis Treatment: by Application USD Million (2025-2030)
  • Figure 33. Global Nonalcoholic Steatohepatitis Treatment: by Distribution USD Million (2025-2030)
  • Figure 34. Global Nonalcoholic Steatohepatitis Treatment: by Medication USD Million (2025-2030)
  • Figure 35. Global Nonalcoholic Steatohepatitis Treatment: by End User USD Million (2025-2030)
  • Figure 36. South America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 37. Asia Pacific Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 38. Europe Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 39. MEA Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 40. North America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan plc. (United States)
  • Cadila Healthcare Limited (India)
  • Conatus Pharmaceuticals Inc. (United States)
  • Galmed Pharmaceuticals Ltd (Israel)
  • Gemphire Therapeutics Inc. (United States)
  • Genfit SA (France)
  • Gilead Sciences, Inc. (United States)
Additional players considered in the study are as follows:
Intercept Pharmaceuticals, Inc. (United States) , Novartis International AG (Switzerland) , Shire Plc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 222 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nonalcoholic Steatohepatitis Treatment Market Quantitative research analysis
Global Nonalcoholic Steatohepatitis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Nonalcoholic Steatohepatitis Treatment Market are by type [Lifestyle Modifications, Dietary Changes and Exercise], by end use application [Health and Nutrition Tracking Apps and Medication Management Tools].
The Nonalcoholic Steatohepatitis Treatment Market is gaining popularity and expected to see strong valuation by 2030.
  • Prevalence of Nonalcoholic Steatohepatitis Cases
  • High Investment in Pharmaceutical R&D

Know More About Global Nonalcoholic Steatohepatitis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Direct Endoscopic Necrosectomy Comprehensive Study by Type (Abdominal Scan, X-ray, Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Abdominal Biopsy, Urine test...
$ 3500
Lyme Disease Treatment Comprehensive Study by Type (Doxycycline, Amoxicillin, Cefuroxime axetil, Ceftriaxone, Others), Application (Humans, Animals), Disease (Early Lyme disease (absence of erythema ...
$ 3750
Acne Scar Treatment Comprehensive Study by Type (Laser Treatments, Minor Skin Surgeries, Chemical Peels, Fillers, Others), Application (Minimize Small Scars, Minor Skin Surface Irregularities, Surgic...
$ 3450
Genital Warts Treatment Comprehensive Study by Drug Type (Podophyllotoxin, Imiquimod, Sinecatechins, Podophyllin, 5-FU), Mechanism of Action (Immunomodulators, Immunomodulators; Virus Internalization...
$ 3650
Pancreatic Amylase Reagent Comprehensive Study by Function (Digestion Of Carbohydrate, Producing Glucose), Causes And Risk Factor (Autoimmune diseases, Drinking lots of alcohol, Infections, Gallstone...
$ 3750
Agoraphobia Treatment Comprehensive Study by Application (Hospitals, Specialty Clinic Center, Others), Therapy (Psychotherapy, Cognitive Behavioral Therapy (CBT), Exposure Therapy, Other), Medication...
$ 3650